Use of a post-sleep questionnaire-interactive voice response system (PSQ-IVRS) to evaluate the subjective sleep effects of ramelteon in adults with chronic insomnia

Sleep Medicine

Volumn 12, Issue 9, 2011, Pages 920-923

  Wang Weigand, Sherry ^a   Watissée, Marie ^b   Roth, Thomas ^c  

^a Takeda Pharmaceuticals International   (United States)

^b Takeda Global Research and Development Centre Europe   (United Kingdom)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

Hypnotic; Insomnia; Melatonin receptor agonist; Polysomnography; Post sleep questionnaire; Sleep latency

Indexed keywords

PLACEBO; RAMELTEON;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; EVENING DOSAGE; FEMALE; HOME CARE; HUMAN; INSOMNIA; LATENT PERIOD; MAJOR CLINICAL STUDY; MALE; POSTSLEEP QUESTIONNAIRE INTERACTIVE VOICE RESPONSE SYSTEM; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; DISORDERS OF EXCESSIVE SOMNOLENCE; FEMALE; HUMANS; INDENES; MALE; MIDDLE AGED; PLACEBOS; POLYSOMNOGRAPHY; QUESTIONNAIRES; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; REPRODUCIBILITY OF RESULTS; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; TELECOMMUNICATIONS; YOUNG ADULT;

EID: 80455164535     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2011.06.008     Document Type: Article

References (17)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR), 4th ed. (Text Revision). Washington, DC: American Psychiatric Association; 2000.
2. Bolge S., Doan J., Kannan H., Baran R. Association of insomnia with quality of life, work productivity, and activity impairment. Qual Life Res 2009, 18(4):415-422.
3. Roth T. Insomnia: definition, prevalence, etiology, and consequences. J Clin Sleep Med 2007, 3(Suppl. 5):S7-10.
4. Takeda Pharmaceuticals North America. Rozerem [package insert]. 2010. Deerfield, IL.
5. Kato K., Hirai K., Nishiyama K., Uchikawa O., Fukatsu K., Ohkawa S., et al. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005, 48(2):301-310.
6. Johnson M., Suess P., Griffiths R. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects. Arch Gen Psychiatry 2006, 63(10):1149-1157.
7. Roth T., Seiden D., Wang-Weigand S., Zhang J. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007, 23(5):1005-1014.
8. Erman M., Seiden D., Zammit G., Sainati S., Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006, 7(1):17-24.
9. Mayer G., Wang-Weigand S., Roth-Schechter B., Lehmann R., Staner C., Partinen M. Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic, primary insomnia. Sleep 2009, 32(3):351-360.
10. Zammit G., Erman M., Wang-Weigand S., Sainati S., Zhang J., Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007, 3(5):495-504.
11. Roth T., Seiden D., Sainati S., Wang-Weigand S., Zhang J., Zee P. Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006, 7(4):312-318.
12. Richardson G., Zammit G., Wang-Weigand S., Zhang J. Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: A 1-year, open-label study. J Clin Psychiatry 2009, 70(4):467-476.
13. Zammit G., Wang-Weigand S., Rosenthal M., Peng X. Effect of ramelteon on middle-of-the-night balance in older adults with chronic insomnia. J Clin Sleep Med 2009, 5(1):34-40.
14. European Medicines Agency Committe for Medicinal Products for Human Use. Guidelines on medicinal products for the treatment of insomnia. EMA/CHMP/16274/2009. Effective: Feb 17 2011 [cited May 10 2011].Available from: URL: http://www.ema.europa.eu/ema.
15. U.S. Department of Health and Human Services Food and Drug Administration. Guidelines for the clinical evaluation of hypnotic drugs. HEW(FDA) 78-3051. Effective: Sep 1 1977 [cited May 10 2011].Available from: URL: http://www.fda.gov.
16. Silva G., Goodwin J., Sherrill D., Arnold J., Bootzin R., Smith T., et al. Relationship between reported and measured sleep times: the sleep heart health study (SHHS). J Clin Sleep Med 2007, 3(6):622-630.
17. Hajak G., Ferini-Strambi L., Wang-Weigand S., Waldron E., Roth T. Objective and subjective efficacy of ramelteon 4mg in adults with chronic insomnia. European Neuropsychopharmacol 2009, 19(Suppl. 3):S354-S355.